Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yasuteru Fujino is active.

Publication


Featured researches published by Yasuteru Fujino.


Endoscopy | 2013

Mucosectom2-short blade for safe and efficient endoscopic submucosal dissection of colorectal tumors.

Koichi Okamoto; Shinji Kitamura; Naoki Muguruma; Toshi Takaoka; Yasuteru Fujino; Yoshiro Kawahara; Toshiya Okahisa; Tetsuji Takayama

BACKGROUND AND STUDY AIMS Endoscopic submucosal dissection (ESD) in the colon has rapidly come into widespread use. However, as complications such as bleeding and perforation often occur, and the procedure time is longer for ESD than for endoscopic mucosal resection (EMR), development of safer and more reliable devices are required especially for colorectal ESD. We report on a new device, the Mucosectom2-short blade (M2-SB) for colorectal ESD and describe its safety and efficacy. PATIENTS AND METHODS The study included 30 patients with lesions diagnosed as colorectal tumor: a nongranular-type laterally spreading tumor (LST) larger than 20 mm or a granular-type LST larger than 30 mm, or lesions that were evaluated as being difficult to remove even by piecemeal EMR. RESULTS All lesions were resected en bloc using this new device, with free lateral and vertical margins. The procedure time was 61 minutes and there was no bleeding or perforation related to the procedure. CONCLUSION The M2-SB seems to be a safe and efficient tool for colorectal ESD.


British Journal of Cancer | 2015

B-RAF mutation and accumulated gene methylation in aberrant crypt foci (ACF), sessile serrated adenoma/polyp (SSA/P) and cancer in SSA/P

Atsushi Inoue; Koichi Okamoto; Yasuteru Fujino; Tadahiko Nakagawa; Naoki Muguruma; Katsutaka Sannomiya; Yasuhiro Mitsui; Toshi Takaoka; Shinji Kitamura; Hiroshi Miyamoto; Toshiya Okahisa; T Fujimori; Issei Imoto; Tetsuji Takayama

Background:Sessile serrated adenomas/polyps (SSA/Ps) are a putative precursor of colon cancer with microsatellite instability (MSI). However, the developmental mechanism of SSA/P remains unknown. We performed genetic analysis and genome-wide DNA methylation analysis in aberrant crypt foci (ACF), SSA/P, and cancer in SSA/P specimens to show a close association between ACF and the SSA/P-cancer sequence. We also evaluated the prevalence and number of ACF in SSA/P patients.Methods:ACF in the right-side colon were observed in 36 patients with SSA/Ps alone, 2 with cancers in SSA/P, and 20 normal subjects and biopsied under magnifying endoscopy. B-RAF mutation and MSI were analysed by PCR–restriction fragment length polymorphism (RFLP) and PCR–SSCP, respectively, in 15 ACF, 20 SSA/P, and 2 cancer specimens. DNA methylation array analysis of seven ACF, seven SSA/P, and two cancer in SSA/P specimens was performed using the microarray-based integrated analysis of methylation by isochizomers (MIAMI) method.Results:B-RAF mutations were frequently detected in ACF, SSA/P, and cancer in SSA/P tissues. The number of methylated genes increased significantly in the order of ACF<SSA/P<cancer. The most commonly methylated genes in SSA/P were PQLC1, HDHD3, RASL10B, FLI1, GJA3, and SLC26A2. Some of these genes were methylated in ACF, whereas all genes were methylated in cancers. Immunohistochemistry revealed their silenced expression. Microsatellite instability and MLH1 methylation were observed only in cancer. The prevalence and number of ACF were significantly higher in SSA/P patients than in normal subjects. A significant correlation was seen between the numbers of SSA/P and ACF in SSA/P patients.Conclusions:Our results suggest that ACF are precursor lesions of the SSA/P-cancer sequence in patients with SSA/P, where ACF arise by B-RAF mutation and methylation of some of the six identified genes and develop into SSA/Ps through accumulated methylation of these genes.


Journal of Gastroenterology and Hepatology | 2015

Serum diamine oxidase activity as a predictor of gastrointestinal toxicity and malnutrition due to anticancer drugs.

Jinsei Miyoshi; Hiroshi Miyamoto; Takahiro Goji; Tatsuya Taniguchi; Tetsu Tomonari; Masahiro Sogabe; Tetsuo Kimura; Shinji Kitamura; Koichi Okamoto; Yasuteru Fujino; Naoki Muguruma; Toshiya Okahisa; Tetsuji Takayama

Objective evaluation of intestinal mucosal damage due to anticancer drugs is generally difficult. Serum diamine oxidase (DAO) activity is reported to reflect the integrity and maturity of the small intestinal mucosa. Therefore, we investigated whether serum DAO activity is an indicator of gastrointestinal toxicity or nutritional status in patients receiving chemotherapy.


Cancer Science | 2017

Downregulation of microRNA-100/microRNA-125b is associated with lymph node metastasis in early colorectal cancer with submucosal invasion

Yasuteru Fujino; Shunsaku Takeishi; Kensei Nishida; Koichi Okamoto; Naoki Muguruma; Tetsuo Kimura; Shinji Kitamura; Hiroshi Miyamoto; Akiko Fujimoto; Jun Higashijima; Mitsuo Shimada; Kazuhito Rokutan; Tetsuji Takayama

A majority of early colorectal cancers (CRCs) with submucosal invasion undergo surgical operation, despite a very low incidence of lymph node metastasis. Our study aimed to identify microRNAs (miRNAs) specifically responsible for lymph node metastasis in submucosal CRCs. MicroRNA microarray analysis revealed that miR‐100 and miR‐125b expression levels were significantly lower in CRC tissues with lymph node metastases than in those without metastases. These results were validated by quantitative real‐time PCR in a larger set of clinical samples. The transfection of a miR‐100 or miR‐125b inhibitor into colon cancer HCT116 cells significantly increased cell invasion, migration, and MMP activity. Conversely, overexpression of miR‐100 or miR‐125b mimics significantly attenuated all these activities but did not affect cell growth. To identify target mRNAs, we undertook a gene expression array analysis of miR‐100‐silenced HCT116 cells as well as negative control cells. The Ingenuity Pathway Analysis, TargetScan software analyses, and subsequent verification of mRNA expression by real‐time PCR identified mammalian target of rapamycin (mTOR) and insulin‐like growth factor 1 receptor (IGF1R) as direct, and Fas and X‐linked inhibitor‐of‐apoptosis protein (XIAP) as indirect candidate targets for miR‐100 involved in lymph node metastasis. Knockdown of each gene by siRNA significantly reduced the invasiveness of HCT116 cells. These data clearly show that downregulation of miR‐100 and miR‐125b is closely associated with lymph node metastasis in submucosal CRC through enhancement of invasion, motility, and MMP activity. In particular, miR‐100 may promote metastasis by upregulating mTOR, IGF1R, Fas, and XIAP as targets. Thus, miR‐100 and miR‐125b may be novel biomarkers for lymph node metastasis of early CRCs with submucosal invasion.


Medicine | 2015

Investigation of Gastroduodenal Mucosal Injury in Japanese Asymptomatic Antiplatelet Drug Users.

Masahiro Sogabe; Toshiya Okahisa; Yasuteru Fujino; Yasuhiro Mitsui; Yoshihumi Takaoka; Tetsuo Kimura; Koichi Okamoto; Naoki Muguruma; Tetsuji Takayama

AbstractAntiplatelet drugs are widely used for the prevention of cardiovascular disease and cerebral vascular disorders. Although there have been several studies on gastroduodenal mucosal injury with gastrointestinal (GI) symptoms such as GI bleeding, in antiplatelet drug users (including low-dose aspirin (LDA)), there have been few reports on the association between antiplatelet drug use and gastroduodenal mucosal injury in asymptomatic antiplatelet drug users. This study was a cross-sectional study elucidating the association between antiplatelet drug use and gastroduodenal mucosal injury in asymptomatic antiplatelet drug users.Subjects were 186 asymptomatic Japanese antiplatelet drug users who underwent a regular health checkup. Subjects were divided into those with and without gastroduodenal mucosal injury endoscopically, and the association between gastroduodenal mucosal injury and other data in asymptomatic antiplatelet drug users was investigated.The prevalence of males and drinkers were significantly higher in subjects with gastroduodenal mucosal injury than in those without. In addition, the prevalence of proton pump inhibitor (PPI) users was significantly lower in subjects with gastroduodenal mucosal injury than in subjects without gastroduodenal mucosal injury. Logistic regression analysis showed PPI (odds ratios: 0.116; 95% confidence intervals: 0.021–0.638; P < 0.05) was a significant predictor of a decreased prevalence of gastroduodenal mucosal injury and closed-type (C-type) atrophy (3.172; 1.322–7.609; P < 0.01) was a significant predictor of an increased prevalence of severe gastroduodenal mucosal injury in asymptomatic antiplatelet drug users.Gender and lifestyle, such as drinking, may have an impact on risk of gastroduodenal mucosal injury in asymptomatic subjects taking antiplatelet drugs. Although PPI is a significant predictor of a decreased prevalence of gastroduodenal mucosal injury, including in asymptomatic antiplatelet drug users, status of gastric atrophy should also be considered against severe gastroduodenal mucosal injury.


Endoscopy International Open | 2018

Linked color imaging enhances endoscopic detection of sessile serrated adenoma/polyps

Daisaku Fujimoto; Naoki Muguruma; Koichi Okamoto; Yasuteru Fujino; Kaizo Kagemoto; Yasuyuki Okada; Yoshifumi Takaoka; Yasuhiro Mitsui; Shinji Kitamura; Tetsuo Kimura; Hiroshi Miyamoto; Yoshimi Bando; Tomoko Sonoda; Tetsuji Takayama

Background and study aims  Although new image-enhanced endoscopy (IEE) technologies such as blue laser imaging (BLI), BLI-bright, and linked color imaging (LCI) have been developed, their utility for the detection of sessile serrated adenoma/polyps (SSA/Ps) is still unclear. This study aimed to evaluate the utility of BLI, BLI-bright, and LCI for SSA/P detection in still image examinations and in a prospective randomized controlled trial (RCT). Patients and methods  A group of 6 expert and non-expert endoscopists read 200 endoscopic still images containing SSA/P lesions using white light image (WLI), BLI, BLI-bright, and LCI. Color differences were calculated using the color space method. A prospective RCT of tandem colonoscopy with WLI and LCI was performed. Patients with SSA/P and those with a history of SSA/P that had been endoscopically removed were enrolled and randomly allocated to WLI-LCI or LCI-WLI groups. Additional endoscopic detection rates for SSA/P were compared between the 2 groups. Results  LCI showed the highest SSA/P detection rate among the 4 modes for both expert and non-expert endoscopists. The detection rate with LCI for the 6 expert endoscopists (mean 98.3 ± standard deviation 2.0 %) was significantly higher than that with WLI (86.7 ± 6.0 %, P  < 0.01). Likewise, the detection rate with LCI for the 6 non-expert endoscopists (92.3 ± 2.9 %) was significantly higher than that with WLI (72.7 ± 11.5 %, P  < 0.01). The color difference of SSA/P with LCI was the highest among the 4 modes, and was significantly higher than with WLI (median 15.9, (interquartile range 13.7 – 20.6) vs. 10.2, (7.6 – 14.2); P  < 0.0001). In the RCT, a total of 44 patients (WLI-LCI 22 vs. LCI-WLI 22) underwent colonoscopy. The additional detection rate for SSA/P in the second inspection in the WLI-LCI group (21.6 %, 8/37) was significantly higher than in the LCI-WLI group (3.2 %, 1/31; P  = 0.02). The small, flat, non-mucus and isochromatic SSA/Ps in the transverse colon were detected more frequently in the second inspection with LCI. Conclusions  LCI was the most sensitive mode for SSA/P detection among WLI, BLI, BLI-bright, and LCI in the still image examinations. Our RCT strongly suggests that LCI is superior to conventional WLI for SSA/P detection during colonoscopy. UMIN000017599.


Gastroenterology | 2014

Tu1725 Angiogenesis-Related Factors At the Residual Inflammation in Patients With Ulcerative Colitis in Clinical Remission Stage

Miwako Kagawa; Toshiya Okahisa; Yoshifumi Takaoka; Yasuteru Fujino; Jinsei Miyoshi; Toshi Takaoka; Tetsu Tomonari; Shinji Kitamura; Yasuyuki Okada; Kaizo Kagemoto; Masanori Takehara; Kumiko Tanaka; Sayo Matsumoto; Tomofumi Teramae; Hiroshi Miyamoto; Naoki Muguruma; Tetsuji Takayama

Angiogenesis-Related Factors At the Residual Inflammation in Patients With Ulcerative Colitis in Clinical Remission Stage Miwako Kagawa, Toshiya Okahisa, Yoshifumi Takaoka, Yasuteru Fujino, Jinsei Miyoshi, Toshi Takaoka, Tetsu Tomonari, Shinji Kitamura, Yasuyuki Okada, Kaizo Kagemoto, Masanori Takehara, Kumiko Tanaka, Sayo Matsumoto, Tomofumi Teramae, Hiroshi Miyamoto, Naoki Muguruma, Tetsuji Takayama


Cancer Chemotherapy and Pharmacology | 2014

Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy.

Yasuhiro Mitsui; Yasushi Sato; Hiroshi Miyamoto; Yasuteru Fujino; Toshi Takaoka; Jinsei Miyoshi; Miwako Kagawa; Hiroyuki Ohnuma; Masahiro Hirakawa; Tomohiro Kubo; Takahiro Osuga; Tamotsu Sagawa; Yasuhiro Sato; Yasuo Takahashi; Shinich Katsuki; Toshinori Okuda; Rishu Takimoto; Masayoshi Kobune; Takayuki Nobuoka; Koichi Hirata; Junji Kato; Tetsuji Takayama


Cancer Chemotherapy and Pharmacology | 2015

A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer

Takahiro Goji; Tetsuo Kimura; Hiroshi Miyamoto; Masanori Takehara; Kaizo Kagemoto; Yasuyuki Okada; Jun Okazaki; Yoshifumi Takaoka; Yoshihiko Miyamoto; Yasuhiro Mitsui; Sayo Matsumoto; Tatsuhisa Sueuchi; Kumiko Tanaka; Yasuteru Fujino; Toshi Takaoka; Shinji Kitamura; Koichi Okamoto; Masako Kimura; Masahiro Sogabe; Naoki Muguruma; Toshiya Okahisa; Yasuhiro Sato; Tamotsu Sagawa; Koji Fujikawa; Yasushi Sato; Hitoshi Ikushima; Tetsuji Takayama


Endoscopy | 2012

A new large-diameter overtube for endoscopic submucosal dissection in the colon

Koichi Okamoto; Naoki Muguruma; Shinji Kitamura; Yasuteru Fujino; Takahiro Goji; Hiromi Yano; Tetsuo Kimura; Hiroshi Miyamoto; Toshiya Okahisa; Tetsuji Takayama

Collaboration


Dive into the Yasuteru Fujino's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hiroshi Miyamoto

University of Rochester Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hiroshi Miyamoto

University of Rochester Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge